Prostate Cancer - Results from #28640

Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners - Abstract February 4, 2011

Dana-Farber researchers identify molecular predictor of metastatic prostate cancer February 3, 2011

Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer - Abstract February 3, 2011

Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer- Abstract February 3, 2011

Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans - Abstract February 3, 2011

Editor's Commentary - Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing February 2, 2011

Abiraterone acetate significantly improved overall survival for patients with metastatic advanced prostate cancer October 11, 2010

Study of investigational agent abiraterone acetate for metastatic advanced prostate cancer unblinded after meeting pre-determined criteria September 10, 2010

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics - Abstract May 31, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

5A prospective survey of current prostate biopsy practices among oncological urologists - Abstract April 29, 2010

Management of Urological Cancers During Pregnancy April 7, 2010

Editorial - Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer March 30, 2010

Abiraterone acetate for castration resistant prostate cancer - Abstract March 29, 2010

GU Cancers Symposium 2010: ASCO ASTRO SUO - Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC) - March 9, 2010

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy - Abstract March 2, 2010

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with Docetaxel-treated castration-resistant prostate cancer - Abstract March 1, 2010

Significant and sustained antitumor activity in post-Docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate - Abstract March 1, 2010

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer - Abstract February 8, 2010

Page 1433 of 1435